Journal: Taiwanese journal of obstetrics & gynecology

Article Title: Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

doi: 10.1016/j.tjog.2018.11.027

Figure Lengend Snippet: Fig. 1. Relationship between constitutive phospho-c-MET expression and cell viability after treatment with BMS-777607. (A) Western blot analysis of total c-MET and phospho-c-MET expression in various human ovarian cancer cell lysates. (B) MTT assay of SKOV3, ES-2, and A2780 cells co-cultured in media containing various concentra- tions of BMS-777607 for 72 h. The results demonstrated that the SKOV3 cells with constitutively phosphorylated c-MET were more sensitive to BMS-777607 than the ES- 2 cells with overexpressed c-MET and c-MET-negative A2780 cells. Error bars in the figure represents the standard error. *p < 0.05, ***p < 0.0001.

Article Snippet: BMS-777607 was purchased from MedChemExpress (Monmouth Junction, NJ).

Techniques: Expressing, Western Blot, MTT Assay, Cell Culture

Journal: Taiwanese journal of obstetrics & gynecology

Article Title: Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

doi: 10.1016/j.tjog.2018.11.027

Figure Lengend Snippet: Fig. 2. Effects of BMS-777607 on c-MET-associated signaling pathways and behavior of the SKOV3 cells. (A) Western blot of c-MET signaling-associated proteins of the SKOV3 cells treated with BMS-777607. (B) Cell apoptosis assays. The percentage of apoptotic cells was determined through flow cytometry based on PI and annexin V staining. (C) Wound healing analysis. These results imply that inhibition of c-MET phosphorylation by BMS-777607 can increase apoptosis and inhibit the migration of SKOV3 cells. Bars in each chart in this figure represent the standard error. *p < 0.05; **p < 0.001; ***p < 0.0001.

Article Snippet: BMS-777607 was purchased from MedChemExpress (Monmouth Junction, NJ).

Techniques: Protein-Protein interactions, Western Blot, Cytometry, Staining, Inhibition, Phospho-proteomics, Migration

Journal: Taiwanese journal of obstetrics & gynecology

Article Title: Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

doi: 10.1016/j.tjog.2018.11.027

Figure Lengend Snippet: Fig. 3. Effect of BMS-777607 on mitosis in SKOV3 cells. (A) Western blot of cell cycle- and mitosis-associated proteins in SKOV3 cells treated with BMS-777607 for 48 h. (B) Immunofluorescent staining of a-tubulin in SKOV3 cells treated with BMS-777607. The colors red and blue in the figure represent tubulin and DNA, respectively. (C) Flow cytometric analysis of cell cycle with PI DNA staining in SKOV3 cells treated with BMS-777607. (D) Changes in the nuclear morphology of the SKOV3 cells treated with BMS-777607. These data demonstrate that BMS-777607 can affect the cell cycle, mitosis regulation, protein expression, and Histone H3 phosphorylation in SKOV3 cells. The SKOV3 cells treated with BMS- 777607 also induced a-tubulin assembling disorder and polyploidy.

Article Snippet: BMS-777607 was purchased from MedChemExpress (Monmouth Junction, NJ).

Techniques: Western Blot, Staining, Expressing, Phospho-proteomics

Journal: Taiwanese journal of obstetrics & gynecology

Article Title: Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

doi: 10.1016/j.tjog.2018.11.027

Figure Lengend Snippet: Fig. 4. In vivo antitumor effects of BMS-777607 in SKOV3 cells constitutively expressing phosphorylated c-MET 50 mg/kg of BMS-777607 daily was orally administered to SKOV3 cell xenograft nude mice (water was administered to the control mice). The tumor sizes were monitored using an IVIS system. The tumor burden was proportional to the size of cell dissemination area. The results demonstrated inhibition of tumor growth (p ¼ 0.0439, control versus BMS-777607) and reduction in tumor burden (p ¼ 0.0091, control versus BMS- 777607) due to BMS-777607 treatment in the ovarian cancer cells with constitutively phosphorylated c-MET. Error bars in each chart represent the standard error.

Article Snippet: BMS-777607 was purchased from MedChemExpress (Monmouth Junction, NJ).

Techniques: In Vivo, Expressing, Control, Inhibition

Journal: eLife

Article Title: EGFR transactivates RON to drive oncogenic crosstalk

doi: 10.7554/eLife.63678

Figure Lengend Snippet: ( A and B ) A431 RON cells were pre-treated with 10 μM afatinib (Afat, pan-ErbB inhibitor) or 1 μM BMS777607 (BMS, Met family kinase inhibitor) for 20 or 15 min, respectively. Cells were then treated ± EGF or MSP for 5 min. ( A ) Cell lysates were used for PY1068 and EGFR immunoblots. ( B ) Lysates were immunoprecipitated (IP) with an anti-HA antibody and then immunoblotted for PY and RON. All samples are from the same blot, but an extraneous lane was removed for clarity. Bar graphs are corresponding mean ± SD from triplicate biological experiments. * p < 0.05; ** p < 0.01; *** p < 0.001. Figure 5—source data 1. Full raw western blots and blots with relevant bands labelled, corresponding to . Figure 5—source data 2. Source data for quantification of blots in .

Article Snippet: Afatinib and BMS777607 were from Selleck Chemicals (cat # S1011 and S1561, respectively), dasatinib from Santa Cruz Biotechnology (cat # sc-358114), and PD153035 from EMD Millipore (cat # 234491).

Techniques: Western Blot, Immunoprecipitation

Journal: eLife

Article Title: EGFR transactivates RON to drive oncogenic crosstalk

doi: 10.7554/eLife.63678

Figure Lengend Snippet:

Article Snippet: Afatinib and BMS777607 were from Selleck Chemicals (cat # S1011 and S1561, respectively), dasatinib from Santa Cruz Biotechnology (cat # sc-358114), and PD153035 from EMD Millipore (cat # 234491).

Techniques: Stable Transfection, Transfection, Plasmid Preparation, Construct, Generated, Cytometry, Kinase Assay, Recombinant, Sequencing, Ligation, Mutagenesis, Bicinchoninic Acid Protein Assay, Expressing, Software, Magnetic Beads